新辅助内分泌治疗后Ki-67指数作为ER阳性/HER2阴性早期乳腺癌患者预后生物标志物的系统综述与Meta分析
该系统综述与Meta分析纳入12项研究共7897例ER阳性/HER2阴性早期乳腺癌患者,评估新辅助内分泌治疗(NET)后Ki-67指数的预后价值。结果显示NET后高Ki-67与无复发生存(RFS)更差(HR 2.48,95%CI 1.86-3.30)和总生存(OS)更差(HR 2.66,95%CI 1.65-4.28)显著相关。
要点
- NET后高Ki-67与更差RFS显著相关(HR 2.48,95%CI 1.86-3.30)。
- NET后高Ki-67与更差OS显著相关(HR 2.66,95%CI 1.65-4.28)。
- 仅在NET 2-4周核心活检中评估Ki-67的敏感性分析显示与RFS的关联相似(HR 2.41,95%CI 1.77-3.30)。
核心结论
- NET后高Ki-67与更差的生存结局相关,即使在短疗程NET后也是如此,强调了该生物标志物在ER阳性/HER2阴性早期乳腺癌女性中的预后价值。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase、CENTRAL和会议论文集至2023年8月22日,纳入报告NET后Ki-67指数与RFS和/或OS关联的研究。
- 共分析12项研究、7897例患者;多数为临床试验(n=7547),仅纳入绝经后女性(n=3953),接受芳香化酶抑制剂治疗(n=3359)。
- 3项研究在NET 2-4周的计划核心活检中评估Ki-67(n=3348),9项研究在NET 2-24周后的手术标本中评估Ki-67(n=4549)。
- RFS的中位随访范围为37至95个月,OS的中位随访范围为62至84个月。
主要发现
- NET后高Ki-67指数与更差RFS显著相关(HR 2.48,95%CI 1.86-3.30)。
- NET后高Ki-67指数与更差OS显著相关(HR 2.66,95%CI 1.65-4.28)。
- 包含3项在计划核心活检中测量Ki-67研究的敏感性分析显示与RFS的关联相似(HR 2.41,95%CI 1.77-3.30)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant treatment discriminates responders, but pathologic complete response is uncommon in oestrogen receptor (ER)-positive/HER2-negative early breast cancer. We aimed to assess the prognostic value of Ki-67 index after neoadjuvant endocrine therapy (NET). METHODS: We conducted a systematic literature search of PubMed, Embase, CENTRAL, and conference proceedings up to 22nd August 2023 to identify studies reporting the association of Ki-67 index after NET with recurrence-free survival (RFS) and/or overall survival (OS) in women with ER-positive/HER2-negative early breast cancer. We combined RFS and OS hazard ratios (HRs) with 95% confidence intervals (CIs). RESULTS: Twelve studies including 7897 patients were analysed. Most studies were clinical trials (n = 7547) including only postmenopausal women (n = 3953) treated with aromatase inhibitor (n = 3359). Three studies evaluated Ki-67 in a preplanned core biopsy at 2-4 weeks of NET (n = 3348), while nine evaluated Ki-67 in the surgical specimen (n = 4549) after 2-24 weeks of NET. Median follow-up ranged between 37 and 95 months for RFS and 62-84 months for OS. High Ki-67 index after NET was significantly associated with worse RFS (HR 2.48, 95% CI 1.86-3.30) and OS (HR 2.66, 95% CI 1.65-4.28). A sensitivity analysis including three studies that measured Ki-67 in a preplanned core biopsy showed similar association with RFS (HR 2.41, 95% CI 1.77-3.30). CONCLUSIONS: High Ki-67 after NET is associated with worse survival outcomes, even after a short course of NET, emphasising the prognostic value of this biomarker in women with ER-positive/HER2-negative early breast cancer.
引用
- Martins-Branco D, Nader-Marta G, Molinelli C, et al. Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis. Eur J Cancer. 2023. PMID: 37857118. doi:10.1016/j.ejca.2023.113358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。